92: Long-term outcomes of proximal gastrectomy for upper third advanced gastric and Siewert type II esophagogastric junction cancers in comparison with total gastrectomy: a propensity-score matched analysis

Friday, March 24, 2023

10:21 AM – 10:31 AM

Location: Ballroom A

Abstract Presenter(s)

Do Joong Park, MD, PhD

Professor
Seoul National University Hospital
Seoul, Republic of Korea

Disclosure(s): Daewoong Pharmaceutical: Research Grant (Ongoing); Inno-N: Research Grant (Ongoing); Johnson & Johnson: Research Grant (Ongoing); JW Pharmaceutical: Research Grant (Ongoing); Medtronic: Research Grant (Ongoing)

First Author(s)

Do Joong Park, MD, PhD

Professor
Seoul National University Hospital
Seoul, Republic of Korea

Disclosure(s): Daewoong Pharmaceutical: Research Grant (Ongoing); Inno-N: Research Grant (Ongoing); Johnson & Johnson: Research Grant (Ongoing); JW Pharmaceutical: Research Grant (Ongoing); Medtronic: Research Grant (Ongoing)

Author(s)

YC

Yoon Soo Chae, MD

Doctor
Seoul National University Hospital, United States

Disclosure information not submitted.
JK

Jeesun Kim, MD

Doctor
Seoul National University Hospital, United States

Disclosure information not submitted.
YC

Yo-Seok Cho, MD

Doctor
Seoul National University Hospital, United States

Disclosure information not submitted.
SK

Seong-Ho Kong, MD, PhD

Professor
Seoul National University Hospital, United States

Disclosure information not submitted.
HL

Hyuk-Joon Lee, MD, PhD

Professor
Seoul National University Hospital, United States

Disclosure information not submitted.
HY

Han-Kwang Yang, MD, PhD

Seoul National University Hospital
Seoul, Republic of Korea

Disclosure information not submitted.

Disclosure(s):

Do Joong Park, MD, PhD: Daewoong Pharmaceutical: Research Grant (Ongoing); Inno-N: Research Grant (Ongoing); Johnson & Johnson: Research Grant (Ongoing); JW Pharmaceutical: Research Grant (Ongoing); Medtronic: Research Grant (Ongoing)

Introduction: This study aims to investigate the safety of proximal gastrectomy in upper third advanced gastric cancer (AGC) and Siewert type II esophagogastric junction (EGJ) cancers.

Methods: Patients who underwent proximal gastrectomy (PG) or total gastrectomy (TG) with standard lymph node dissection for pathologically proven upper third AGC and EGJ cancers were enrolled between January 2007 and December 2016. Propensity score matching of 1:1 ratio was conducted to reduce the influence of confounding variables such as age, sex, operation approach, T stage, and N stage. Kaplan-Meier survival analysis was performed to analyze the 3-year disease-free and overall survivals.

Results: Among a total of 7,943 patients with gastrectomy for gastric cancer, 324 patients were enrolled in this study. Of the 324 patients, 51 received PG and 273 received TG. Propensity score matching yielded 51 patients for each group. The 3-year disease free survivals were 88.2% in the PG group and 96.1% in the TG group, respectively (p=0.141). The 3-year overall survivals were 98.0% in the PG group and 100% in the TG group, respectively (P=0.315). PG group showed 6 recurrences (3 anastomosis site, 1 paraaortic LN, 1 Liver, 1 spleen) and TG group showed 2 recurrences (1 peritoneal seeding, 1 spleen).

Conclusions: Patients who underwent PG had the same disease-free and overall survivals as those who underwent TG in AGC & Siewert type II EGJ cancers.

Learning Objectives:

Upon completion, participant will be able to describe the indication of proximal gastrectomy for gastric cancer.
Upon completion, participant will be able to demonstrate the procedure of proximal gastrectomy for gastric cancer.
Upon completion, participant will be able to describe the long-term outcome of proximal gastrectomy for gastric cancer in comparison with total gastrectomy.